Biogen (BIIB) Gets a Buy from Needham
In a report released today, Ami Fadia from Needham maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $300.00. The company’s shares closed today at $279.25.Fadia covers the Healthcare sector…
on TipRanks.com
This article was originally published by Marketwatch.com. Read the original article here.
